Sesen Bio (Nasdaq: SESN) and Carisma Therapeutics have further changed their previously amended merger agreement following investor pushback.
The latest changes appear to satisfy a group of disgruntled shareholders, led by Bradley Radoff and Michael Torok, which together owns around 8.7% of the company.
This time the one-time special cash dividend expected to be paid to Sesen Bio stockholders has been increased to $75 million, a rise of $5 million on the amended amount and of $50 million on the original proposal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze